Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.

Slides:



Advertisements
Similar presentations
NEW ORAL AGENTS IN DIABETES MANAGEMENT
Advertisements

Oral Hypoglycemic Drugs And Classifications
Diabetes Update Matt Bouchonville, MD Endocrinology Division University of New Mexico ACP New Mexico Chapter Scientific Meeting November 7, 2014
 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Implementing Diabetes Guidelines in the “Real World” Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice.
‘Emerging Insulin-Independent Approaches for the Management of Type 2 Diabetes’ Chair: Clifford J. Bailey, PhD Professor of Clinical Science Head of Diabetes.
Farxiga™ - Dapagliflozin
Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
Glycogen Metabolism Storage and Mobilization of Glucose NUTR 543 – Advanced Nutritional Biochemistry David L. Gee, PhD Professor of Food Science and Nutrition.
Oral diabetes Medications
Oral Medications to Treat Type 2 Diabetes
Comparing Medications for Adults With Type 2 Diabetes
ADVANCE IN TREATMENT OF TYPE 2 D.M. BY DR : RAMYAHMED SAMY M.D. LECTURER OF INTERNAL MEDICINE BANHA UNIVERSITY
Barriers to Diabetes Control Mark E. Molitch, MD.
LONG TERM BENEFITS OF ORAL AGENTS
Novel Antidiabetics: Should they be used at all - and in whom?
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.
Diabetes and You Vidya Sundaram, MD. Diabetes in Asian Indians The prevalence of diabetes in rural India is 2 percent The prevalence of diabetes in rural.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

Guidelines for Diabetes Management September 20, 2012 Margaret Pochay RD CDE.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Managing Type 2 Diabetes: Review of Recent Guidelines Gina Ryan, Pharm.D., BCPS, CDE Clinical Associate Professor Mercer University College of Pharmacy.
A Critical Analysis of the Clinical Use of Incretin-Based Therapies The benefits by far outweigh the potential risks Featured Article: Diabetes Care Volume.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Therapy of Type 2 Diabetes Mellitus: UPDATE
New Medications for Diabetes
Adding Prandial Insulin to Basal Insulin: Key Challenges
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
Oral hypoglycemic drugs
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
1 ‘Medicines used in the management of Type 2 Diabetes’ Dr Susan McGeoch, Specialist Registrar in Diabetes Sandra Wilson, Diabetes Specialist Nurse.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Abbey Medical Practice Personalised Diabetic Care Wednesday 10 th September 2014.
Mania Radfar Pharm.D. Novel oral antidiabetic agents.
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Medications Used in the Treatment of Diabetes Mellitus
Drugs for Type 2 Diabetes – where next after metformin ?
Diabetes Learning Event 7th October 2016
6.Fat- increased lipolysis, inc FFA
Neal B, et al. Diabetes Care 2015;38:403–411
Therapeutics Tutoring
Diabetes 2017 & Into The Future
Diabetes 101: Myths and Facts
Diabetes Health Status Report
Empagliflozin (Jardiance®)
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
oral hypoglycemic agents
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
DM management Dr.Duaa Hiasat.
Carbohydrate absorption inhibitors α-glucosidose inhibitors
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Medical Care In Diabetes
DM management Dr.Duaa Hiasat.
Oral hypoglycemics Jennifer R Marks, MD.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University

Factors in deciding between therapies Treatment goals (and how far from goal) Costs Adverse effects, especially hypoglycemia. Need for flexibility, eating patterns Patterns of blood glucose before/after eating Patient characteristics

GLYCEMIC GOALS Diabetes treatment

Treatment goals American Diabetes Association. Standards of Medical Care in Diabetes  Diabetes Care 2015; 38 (S1)

Relationship between “A1c” and blood glucose Nathan D et al., for the A1c-Derived Average Glucose (ADAG) Study Group. Diabetes Care 2008

TREATMENT OPTIONS Diabetes treatment

Lifestyle modifications Increasing physical activity Nutrition therapy Weight loss

diabetesmanager.pbworks.com. Accessed Treatment options

Medications: Metformin How it works AdvantagesDisadvantagesCost ↓ liver glucose production Helps body use insulin better Extensive clinical experience Rare hypoglycemia Likely  CVD events (UKPDS) Weight neutral/loss GI side effects Lactic acidosis risk (rare) Vitamin B12 deficiency Multiple contraindications: CKD, acidosis, hypoxia, dehydration, etc. Low A1c ↓ 1.0–2.0%

Medications: Sulfonylureas (glipizide, glimepiride) How they work AdvantagesDisadvantagesCost  Insulin release from pancreas Extensive experience  microvascular complication (UKPDS) Hypoglycemia Weight gain Low A1c ↓ 1.0–2.0%

Medications: Meglitinides (repaglinide, nateglinide) Mechanism/ Action AdvantagesDisadvantagesCost  Insulin release from pancreas  glucose after eating Flexibility Short duration of action Hypoglycemia Weight gain Multiple daily doses High A1c ↓ %* *repaglinide more effective than nateglinide

Medications: Incretin mimetics Ahren B. Nature Reviews Drug Discovery 2009; 8: 369. GLP-1 analogs x DPP-4 inhibitors +

Medications: GLP-1 analogs (exenatide, liraglutide, dulaglutide) How they work AdvantagesDisadvantagesCost  insulin  glucagon slows gastric emptying  satiety No hypoglycemia Weight loss ? Cardiovascular protective actions GI side effects (nausea/vomiting) Injection Unknown long-term safety ?pancreatitis thyroid c-cell tumors in rodents High A1c ↓ %

Medications: DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) Mechanism/ Action AdvantagesDisadvantagesCost  insulin  glucagon No hypoglycemia Well tolerated modest efficacy ?pancreatitis Severe joint pain ?  risk of heart failure (saxagliptin) Unknown long- term safety High A1c ↓ %

Medications: Thiazolidinediones (pioglitazone,rosiglitazone) How they work AdvantagesDisadvantagesCost Helps body use insulin better (  insulin sensitivity) no hypoglycemia durability improves HDL ? ↓ heart attack (pioglit.) weight gain fluid retention/ heart failure bone fractures  LDL (rosiglit.) ? ↑ heart attack (rosiglit.) ? ↑ bladder cancer (pioglit.) High A1c ↓ 0.5–1.4%

Medications: SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin, etc) How they work AdvantagesDisadvantagesCost  glucose excretion by kidneys  blood glucose  weight  BP Low risk of hypoglycemia  genital mycotic infections, urinary tract infections ? long-term safety of chronic glucosuria hypotension “Euglycemic DKA”  fractures / ↓bone density hypotension High A1c ↓ 0.5 –0.7 %

Medications: Insulin Insulin therapy frequently required due to progressive loss of pancreas (“beta-cell”) function Initial therapy if: –  glucose (e.g., >300 mg/dL) or HbA1c (e.g. >10%) – Significant hyperglycemic symptoms – Necessary when catabolic symptoms or ketonuria (reflects profound insulin deficiency) If no evidence of T1DM, may be possible to taper insulin partially or entirely after symptoms relieved and glucotoxicity resolved

Medications: Insulin Mechanism/A ction AdvantagesDisadvantagesCost ↓ glucose release by the liver moves glucose from blood into muscle/fat Universally effective No dose limit ↓ microvascular disease improved cholesterol Hypoglycemia Weight gain Injection (1 – 4+) Training requirements “Stigma” (for patients)  A1c ↓ 1.0 – 3.5%

Physiologic insulin delivery DeWitt DE et al. JAMA 2003; 289: 2254.

Insulin delivery options

Insulin delivery options

Insulin delivery options

PUTTING IT ALL TOGETHER Diabetes treatment

Treatment of T2DM American Diabetes Association. Standards of Medical Care in Diabetes  Diabetes Care 2015; 38 (S1)